Opinion|Videos|January 5, 2024
Assessing Treatment Response in Patients With Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.
Advertisement
Episodes in this series
Advertisement
Related to this article
Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.
For National Hospice and Palliative Care Month, answers to common questions about how palliative care differs from hospice, who qualifies, what Medicare covers and how to find a program.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
A breast cancer survivor shares how cancer turned gratitude into an everyday practice and why it's OK when the holidays bring both joy and grief this year.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.
After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
Advertisement
Advertisement
Trending on CURE
1
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
2
Keytruda After Kidney Cancer Surgery Lowers Risk of Death by 30%
3
Sac-TMT Plus Keytruda Improves Outcomes in PD-L1-Negative Lung Cancer
4
ACA Open Enrollment 2027: What Patients With Cancer Should Check
5